Abstract:Abstract Objective: CDK4/6 inhibition has become an important treatment option in some epithelial malignancies but its utility in the setting of NSCLC remains limited. While CDK4-based monotherapy has been generally ineffective, combinatorial regimens have shown promise. Here we sought to perform an unbiased assessment of potential combinatorial strategies in pre-clinical models of NSCLC. Methods: We performed a CRISPR/Cas9 screen in two NSCLC cell lines (A549 and H2030) in the presence and absence of the CDK4/6 inhibitor Palbociclib and identified guide RNAs that selectively depleted in the setting of drug treatment. We subsequently performed validation and mechanistic experiments as described. CDK4 and CDK2 activity was assessed using a fluorescent reporter system. Results: Palbociclib-sensitizing screen hits include MAPK1 (ERK2), AKT1, MAP3K2 (MEKK2), PIK3CA, MAPK14 (p38a), AKT3, PORCN, LGR4, CDK1, CDK9, and AURKB. Screen results were compared with a previously published Palbociclib sensitizing screen and shared hits were identified. Of these, CCNE1 was the highest scoring hit suggesting relevance across histologies. Interestingly, several screen hits such as ERK2, PIK3CA, VCP and ELAVL1 have reported roles in CCNE1 transcription or post-translational stabilization suggesting a central role for CCNE1 in determining drug sensitivity. Western blot analyses demonstrate that CCNE1 is rapidly upregulated following Palbociclib exposure in a panel of NSCLC cell lines and immunofluorescence shows strong post-treatment CCNE1 expression in human A549 xenografts in vivo. CDK2/4 fluorescent reporter assays show partial restoration of CDK2 activity within 48 hours of Palbociclib treatment. Genetic validation experiments using dox-inducible shRNA constructs targeting CCNE1 show that CCNE1 knockdown sensitizes cells to Palbociclib treatment and enhances senescence induction. Pharmacologic and genetic co-inhibition of CDK2 improves Palbociclib efficacy yet such co-inhibition further elevates CCNE1 levels and CDK2 suppression remains incomplete based the fluorescence reporting system. Furthermore, knockdown of CCNE1 in conjunction with CDK2/4/6 inhibition shows improved growth inhibition compared to drug treatment alone. Based on this data, we hypothesize that targeting signaling pathways upstream of CCNE1 transcription or those which affect CCNE1 stabilization and turnover may be more efficacious than combined CDK inhibition. Conclusion: CCNE1 is a critical mediator of sensitivity to CDK4/6 inhibition and Palbociclib treatment results in rapid compensatory increases in CCNE1 levels. Despite drug treatment, NSCLC cells retain CDK2 activity which is only partially inhibited by combined CDK 2/4/6 inhibition. Screen results suggest several potential approaches for co-targeting of CCNE1 to enhance drug sensitivity. Citation Format: Matthew Bott, Maria Skamagki, Nelson Salgado, Francisco Sanchez-Rivera, Scott Lowe. Druggable CRISPR/Cas9 screen identifies Cyclin E1 (CCNE1) as a key mediator of sensitivity to CDK4/6 inhibition in non-small cell lung cancer (NSCLC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5990.

Genome-wide CRISPR screens reveal cyclin C as synthetic survival target of BRCA2

Cyclin D1 Silencing Impairs DNA Double Strand Break Repair, Sensitizes BRCA1 Wildtype Ovarian Cancer Cells to Olaparib.

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

The Cdk1 Inhibitor Ro3306 Improves The Response Of Brca-Proficient Breast Cancer Cells To Parp Inhibition

A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC

BRCAness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality

Abstract PR06: CRISPR Screens Identified Drivers of Endocrine Resistance and Synthetic Lethal Vulnerabilities in Breast Cancer

Abstract 5990: Druggable CRISPR/Cas9 screen identifies Cyclin E1 (CCNE1) as a key mediator of sensitivity to CDK4/6 inhibition in non-small cell lung cancer (NSCLC)

Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability

PARP inhibitors suppress tumours via centrosome error-induced senescence independent of DNA damage response

Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy

Effect of BRCA1 on the Concurrent Chemoradiotherapy Resistance of Cervical Squamous Cell Carcinoma Based on Transcriptome Sequencing Analysis.

CRISPR/Cas9‐mediated Mutagenesis to Validate the Synergy Between PARP1 Inhibition and Chemotherapy in BRCA1‐mutated Breast Cancer Cells

Influence of cyclin D1 splicing variants expression on breast cancer chemoresistance via CDK4/CyclinD1-pRB-E2F1 pathway

Abstract PR014: Genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies

Supplementary Tables S1-S4 from the BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4

A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells

Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer

Genomic and Expressional Dynamics of Ovarian Cancer Cell Lines in PARPi Treatment Revealed Mechanisms of Acquired Resistance.